Doxorubicine-Congestive Heart Failure-Increased Big Endothelin-1 Plasma Concentration : Reversal by Amlodipine, Losartan, and Gastric Pentadecapeptide BPC157 in Rat and Mouse

スポンサーリンク

概要

• 論文の詳細を見る

• Overall, doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period) is consistently deteriorating throughout next 14 days, if not reversed or ameliorated by therapy (/kg per day): a stable gastric pentadecapeptide BPC157 (GEPPPGKPADDAGLV, MW 1419, promisingly studied for inflammatory bowel disease (Pliva; PL 10, PLD-116, PL 14736)) (10 μg, 10 ng), losartan (0.7 mg), amlodipine (0.07 mg), given intragastrically (i.g.) (once daily, rats) or in drinking water (mice). Assessed were big endothelin-1 (BET-1) and plasma enzyme levels (CK, MBCK, LDH, AST, ALT) before and after 14 days of therapy and clinical status (hypotension, increased heart rate and respiratory rate, and ascites) every 2 days. Controls (distilled water (5 ml/kg, i.g., once daily) or drinking water (2 ml/mouse per day) given throughout 14 days) exhibited additionally increased BET-1 and aggravated clinical status, while enzyme values maintained their initial increase. BPC157 (10 μg/kg) and amlodipine treatment reversed the increased BET-1 (rats, mice), AST, ALT, CK (rats, mice), and LDH (mice) values. BPC157 (10 ng/kg) and losartan opposed further increase of BET-1 (rats, mice). Losartan reduces AST, ALT, CK, and LDH serum values. BPC157 (10 ng/kg) reduces AST and ALT serum values. Clinical status of CHF-rats and -mice is accordingly improved by the BPC157 regimens and amlodipine.

• 社団法人 日本薬理学会の論文
• 2004-05-20

著者

• BLAGAIC Alenka

  Department of Pharmacology, Medical School, University of Zagreb

• BATELJA Lovorka

  Institute of Pathology, Medical School, University of Zagreb

• SIKIRIC Predrag

  Department of Pharmacology, Medical School, University of Zagreb

• BATELJA Lovorka

  Department of Pharmacology, Medical Faculty, University of Zagreb

• SEIWERTH Sven

  Department of Pharmacology, Medical Faculty, University of Zagreb

• Seiwerth Sven

  Institute Of Pathology University Of Zagreb Medical School

• Blagaic Alenka

  Department Of Pharmacology Medical School University Of Zagreb

• Blagaic Alenka

  Departments Of Pharmacology And Pathology Medical Faculty University Of Zagreb

• Batelja Lovorka

  Institute Of Pathology Medical School University Of Zagreb

• Sikiric Predrag

  Department Of Pharmacology University Of Zagreb Medical School

• LOVRIC-BENCIC Martina

  Department of Pharmacology, Medical Faculty, University of Zagreb

• HANZEVACKI Jadranka

  Department of Pharmacology, Medical Faculty, University of Zagreb

• ROGIC Dunja

  Department of Pharmacology, Medical Faculty, University of Zagreb

• KUSEC Vesna

  Department of Pharmacology, Medical Faculty, University of Zagreb

• ARALICA Gorana

  Department of Pharmacology, Medical Faculty, University of Zagreb

• KONJEVODA Pasko

  Department of Pharmacology, Medical Faculty, University of Zagreb

• Kusec Vesna

  Department Of Pharmacology Medical Faculty University Of Zagreb

• Konjevoda Pasko

  Department Of Pharmacology Medical Faculty University Of Zagreb

• Lovric-bencic Martina

  Department Of Pharmacology Medical Faculty University Of Zagreb

• Hanzevacki Jadranka

  Department Of Pharmacology Medical Faculty University Of Zagreb

• Rogic Dunja

  Department Of Pharmacology Medical Faculty University Of Zagreb

• Aralica Gorana

  Department Of Pharmacology Medical Faculty University Of Zagreb

• Hanzevacki Jadraoka

  Department of Pharmacology, Medical Faculty, University of Zagreb

関連論文

• Prolonged Esophagitis After Primary Dysfunction of the Pyloric Sphincter in the Rat and Therapeutic Potential of the Gastric Pentadecapeptide BPC 157
• An Experimental Model of Prolonged Esophagitis With Sphincter Failure in the Rat and the Therapeutic Potential of Gastric Pentadecapeptide BPC 157
• Pentadecapeptide BPC 157, in Clinical Trials as a Therapy for Inflammatory Bowel Disease (PL14736), Is Effective in the Healing of Colocutaneous Fistulas in Rats : Role of the Nitric Oxide-System
• Gastric Pentadecapeptide BPC 157 as an Effective Therapy for Muscle Crush Injury in the Rat
• Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease (PL-10, PLD-116, PL14736, Pliva, Croatia) Heals Ileoileal Anastomosis in the Rat
• Doxorubicine-Congestive Heart Failure-Increased Big Endothelin-1 Plasma Concentration : Reversal by Amlodipine, Losartan, and Gastric Pentadecapeptide BPC157 in Rat and Mouse

スポンサーリンク